“Over the last year, our progress on two preclinical gene therapy programs as well as our novel AAV capsid discovery platform has been remarkable,” said P. Peter Ghoroghchian, MD, PhD, CEO of Latus.
At AACR 2024, we explored the poster hall to pick out the posters that would interest the BioTechniques reader and those we found delivered the most interesting or surprising findings. Get our ...
LONDON and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings (MGTX) plc , a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit nine poster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results